Heron Therapeutics
HRTX
107 hedge funds and large institutions have $1.21B invested in Heron Therapeutics in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 42 increasing their positions, 22 reducing their positions, and 25 closing their positions.
1,441% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $2.17M
91% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 22
24% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 25
14% more capital invested
Capital invested by funds: $1.06B → $1.21B (+$149M)
5% more funds holding
Funds holding: 102 → 107 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$14.7M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$10.2M |
| 3 |
BC
Broadfin Capital
New York
|
+$9.89M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.74M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$18.4M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$6.32M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.02M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.95M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.29M |
HRTX Hedge Fund Activity: Q4 2015 in Review
107 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2015, worth a combined $1.21B — up 14% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new HRTX positions and 25 closed out — a net gain of 6 holders — while 42 added to existing stakes and 22 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $14.7M. The largest seller was Goldman Sachs, cutting an estimated $18.4M.
- 107 institutional investors held Heron Therapeutics (HRTX) as of Q4 2015, up from 102 in Q3 2015.
- Funds reported $1.21B of Heron Therapeutics stock for Q4 2015, up 14% quarter-over-quarter.
- 31 funds opened new Heron Therapeutics positions in Q4 2015 and 25 closed out, a net change of +6 holders.
- The largest Heron Therapeutics buyer in Q4 2015 was Janus Henderson Investors US, an estimated $14.7M added.
- The largest Heron Therapeutics seller in Q4 2015 was Goldman Sachs, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2015.